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Abstract
Background:  The coinfections HIV/HCV/HBV are an important health issue in penitentiary
communities. The aim of the study was to examine HIV, HBV and HCV coinfections determinants
amongst prisoners in the jails of Southern Lazio (Central Italy), in the period 1995–2000.
Methods: Diagnosis of seropositivities for HIV, HBV and HCV was made using ELISA method. A
multiple logistic regression analysis was conducted to verify the influence of socio-demographic
factors on the HIV/HBV/HCV coinfections.
Results: HIV/HCV, HBV/HCV and HIV/HBV coinfections were detected in 42 (4%), 203 (17.9%)
and 31 (2.9%) inmates, respectively. These coinfections are significantly associated with the status
of drug addiction (OR = 16.02; p = 0.012; OR = 4.15; p < 0.001; OR = 23.57; p = 0.002), smoking
habits (OR = 3.73; p = 0.033; OR = 1.42; p = 0.088; OR = 4.25; p = 0.053) and Italian nationality
(OR = 7.05; p = 0.009; OR = 2.31; p < 0.001; OR = 4.61; p = 0.04).
Conclusion: The prevalence of HIV, HBV and HCV seropositivity in jails suggests that information
and education programs for inmates could be useful to reduce the spread of such infections.
Background
Human Immunodeficiency Virus (HIV) and the hepatitis
C virus (HCV) or hepatitis B virus (HBV) coinfections rep-
resent a public health problem of growing importance.
Because of the similar modes of spread, many people are
coinfected with HIV and HCV, HIV and HBV, and in some
cases with all three viruses at the same time. In particular,
HCV and HIV are called the "twin epidemics": in fact,
both are blood-born RNA viruses that replicate rapidly
and direct blood-to-blood transmission – for example
through needle sharing – is the most efficient means of
transmitting both viruses [1].
Most studies show that HIV infection leads to more
aggressive hepatitis C or hepatitis B and higher risk of liver
damage [1]. Studies of how HCV and HBV affect HIV
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infection are less clear. Most research shows that HCV
does not accelerate HIV disease progression, but HIV/
HCV coinfection may impair immune system recovery
after antiretroviral therapy has commenced [1-3].
Coinfection can complicate treatment. People with liver
damage due to chronic hepatitis are more likely to experi-
ence hepatotoxicity related to anti-HIV drugs, and this
represents a major concern for prison health officials deal-
ing with infected prisoners who need treatment, for both
health management and infections control.
Prisoners are considered to be at high risk of infection
with HIV [6-15] and other viruses (e.g. hepatitis and other
sexually transmitted infections) [16-24] due to the high
proportion of risk related behaviours during the perma-
nence within jails, in particular injecting illegal drugs,
unprotected sexual relations, common use of hypodermic
needles for execution of tattoos or needle sharing [25-31].
In the United States it is estimated that the 12–15% of all
Americans with chronic HBV infection, 39% of those with
chronic HCV and 20–26% of those with HIV infection
have a history of incarceration [32].
Among the population of injection drug users, the HIV/
HCV coinfection rate may be as high as 90% (HIV coinfec-
tion) and it remains high also among populations of pris-
oner [1-5].
A history of drug use is common in detainee populations
in many countries: in the USA 73–83% of prison inmates
misuse drugs [33] while in the Republic of Ireland it is
estimated that 40% of prisoners use drugs. Furthermore,
an Australian study determined that during their incarcer-
ation 25–44% of inmates occasionally injected illegal
drugs, 14–34% engaged in occasional anal intercourse
and 5–18% did both [34].
With regards to the prisoners right to health, in Italy recent
modifications of disposals on execution of punishment,
safety and preventive measures towards prisoners suffer-
ing from HIV/AIDS have been performed [43,44]. Modifi-
cations of penitentiary health systems have the aim of
rationalising the health interventions for prisoners (pre-
ventive, curative and rehabilitative), which are guaranteed
by the Constitution for health services [45].
Because of the seriousness of hepatitis B virus, hepatitis C
virus, and HIV infections among inmates, it is important
to know both the prevalence of these infections and the
patterns of risk related behaviours in prison environ-
ments. We initiated a study concerning the spread of
bloodborne viruses among the prison entrants of South-
ern Lazio (Italy). The aim of this study was to investigate
the association between HIV and hepatitis B and C viruses
coinfections and socio-demographic determinants.
Methods
Study design and Setting
A cross-sectional study was conducted in three jails of
Southern Lazio (Cassino, Frosinone and Latina). The
study was authorized by the Ministry of Justice upon the
presentation of a detailed research protocol (n° 43, 23-6-
2001). A pilot study of 1 month was conducted in Decem-
ber 2000, in order to validate the registration procedures
and the assessment form [46,47]. The survey was carried
out between January 2001- December 2002 and took into
account all male prisoners detained in the above men-
tioned jails during the years 1995–2000.
The research was conducted according to the Helsinki
Declaration.
Data collection
As far as data collection, all the information (including
the testing) in the study came from the patients' chart, so
a retrospective collection was realised. The medical charts
of the prisoners were carefully examined by a public
health doctor and by two social workers. Information
regarding socio-demographic characteristics, life style
habits and health status of prisoners was collected. In par-
ticular, the presence of HIV, HBV and HCV infection was
ascertained testing the seropositivity against these viruses
using the ELISA method. This was feasible because testing
against these viruses is a standard procedure in this set-
ting, including testing inmates that both referred or did
not refer to the jail's clinic for medical reason. In the
present study we considered inmates for which HIV/HCV,
HBV/HCV, HIV/HBV testing were simultaneously present.
Since the prisoners are a vulnerable study population,
their privacy was respected by ensuring that their names
and surnames were not recorded. All of the pertinent data
was transferred onto a specially prepared form and after-
wards transferred into a database.
Statistical analysis
The tables describe the distribution of infections among
inmates according to several characteristics. The χ2 test
was performed in order to investigate the association
between the presence of HIV/HBV/HCV coinfections and
socio-demographic determinants as well as life style hab-
its. The Fisher exact test was used where applicable.
In order to identify risk factors associated to HIV/HCV,
HBV/HCV and HIV/HBV coinfections, three multiple
logistic regression analyses were performed, using the
backward elimination procedure as described by Hosmer
and Lemeshow [48].BMC Infectious Diseases 2007, 7:100 http://www.biomedcentral.com/1471-2334/7/100
Page 3 of 9
(page number not for citation purposes)
The goodness of fit of the regression model was tested
using the Hosmer and Lemeshow test.
The following variables were considered as covariates:
nationality (not Italian as the reference group), civil status
(single as the reference group), age group (age under 35
years as the reference group), educational level (low level
as the reference group), number of previous detentions
(first detention as the reference group), drug addiction
(no addiction as the reference group), use of methadone
(no use as the reference group), presence of Syphilis anti-
bodies (VDRL) (seronegativity as the reference group),
previous sexually transmitted diseases, Tine test result
(negative test as the reference group), alcohol abuse (no
abuse as the reference group) and smoking status (non
smokers as the reference group).
The level of statistical significance was fixed at p = 0.05.
The statistical analysis was performed using the statistical
software SPSS 12.0 for Windows.
Results
HIV/HCV coinfection
With regards to HIV/HCV coinfection, information rela-
tive to 1047 prisoners of male gender (502 from Cassino,
485 from Frosinone and 60 from Latina) were found.
Table 1 shows the socio-demographic characteristics of
the prisoners.
In relation to age, inmates ages were distributed as follow:
20.8% of inmates were 18–24 years of age, 46.4% were
25–34 years of age, 23.5% were 35–44 years of age and
9.3% were over 44 years of age.
The majority of inmates (46.3%) had a junior high school
education and only 1.2%, had an educational level higher
than secondary school. 773 prisoners (73.8%) were Ital-
ian and 274 (26.2%) were of a foreign nationality. 51.5%,
had never been married, 38.2% were currently married or
cohabiting and 10.3% were separated or widower.
In terms of the number of detentions, for 682 prisoners
(68.8%) it was the first episode, while the other 309 per-
sons (31.2%) had at least one other previous experience
of detention. HIV/HCV coinfection was diagnosed in 42
individuals (4% of tested prisoners): 11 in Cassino
(2.2%), 30 in Frosinone (6.2%) and 1 in Latina (1.7%).
Statistically significant differences in HIV/HCV coinfec-
tion were found for the following variables: the jail (p =
0.004), the nationality (p = 0.007), civil status (p <
0.001), age group (p = 0.003) and the number of deten-
tions (p = 0.016).
Table 2 shows characteristics of the 1047 prisoners. With
respect to drug use, 479 prisoners (45.7%), were drug
addicted at the time of incarceration and 52 (5%) were
former addicted.
With regards to the type of drugs used, 429 individuals
(41.0%) were heroin dependent, 264 (25.2%) were
cocaine addicts, while amongst the drug addicts 245 indi-
viduals (85.6%) were methadone consumers. Most indi-
viduals (54.7%) were polydrug abusers.
Table 2 shows prisoners' health characteristics with refer-
ence to their HIV and HCV coinfection status. The χ2 test
showed that the variables significantly associated with
HIV/HCV coinfection were drug addiction (p < 0.001),
use of methadone (p = 0.012) and smoking status (p =
0.002).
The results of the multiple regression analyses are pre-
sented in Table 3. In particular we found that HIV/HCV
coinfection was associated with the status of drug addic-
tion (OR = 16.02; p = 0.012), age group (OR = 2.83; p =
0.004, for people of 35–44 years), civil status (OR = 3.09;
p = 0.007, for cohabitants), smoking habits (OR = 3.73; p
= 0.033) and Italian nationality (OR = 7.05; p = 0.009).
HBV/HCV coinfection
As far as HBV/HCV coinfection was concerned, informa-
tion relating to 1136 prisoners of male gender was distrib-
uted as follows: 510 in Cassino, 494 in Frosinone and 132
in Latina. The HBV/HCV coinfection had been diagnosed
in 203 individuals (17.9% of tested prisoners), with statis-
tically significant differences in the percentages among the
jails (p < 0.001): 56 (2.2%) in Cassino, 96 (19.43%) in
Frosinone and 51 (38.64%) in Latina. With regards to
nationality, 73.4% were Italian and 26.6% were foreign.
Considering those persons with only coinfection, 56.6%
of them were foreign and this difference was statistically
significant (p < 0.001).
Concerning civil status, 51.8% had never been married,
while 30.4% were currently married, 8.1% cohabitant and
9.5% were separated or widower. Statistically significant
differences were found for the following variables: civil
status (p = 0.013), age group (p < 0.001) and educational
level (p = 0.018). In particular, most of the people
(22.49%) were 25–34 years old and had junior high
school degrees (24.08%) (Table 1).
In Table 2 significant differences in HBV/HCV coinfection
group are shown for drug addiction (p < 0.001) and
smoking status (p < 0.001).
Table 3 illustrates the factors associated with HBV-HCV
coinfection, showing that coinfection is significantly asso-BMC Infectious Diseases 2007, 7:100 http://www.biomedcentral.com/1471-2334/7/100
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ciated with drug addiction (OR = 4.15, p < 0.001), age
group (OR = 0.371, p = 0.04, for people over 45 years),
and Italian nationality (OR = 2.31, p < 0.001).
HIV/HBV coinfection
HIV/HBV coinfection was studied in 1076 prisoners and
these numbers were distributed as follows: 505 in Cassino
(46.9%), 511 in Frosinone (47.5%) and 60 (5.6%) in
Latina. The prevalence rate of this coinfection was found
to be 2.9%.
73.1% of the inmates were Italian and 3.56% of them had
HIV/HBV coinfections.
Most of them (51.8%) had never been married, 29.0%
were currently married, 8.7% were cohabitant and 10.5%
were separated or widower.
HBV/HCV coinfection was detected in 5.7% of the prison-
ers with drug addictions, 8.89% in methadone users and
3.8% in those inmates who smoked. With regards to edu-
Table 1: Socio-demographic characteristics of prisoners, according to seropositivity against HIV/HCV, HBV/HCV and HIV/HBV
HIV/HCV HBV/HCV HIV/HBV
Characteris
tic
Total (%) coinfection 
(%)
p Total (%) coinfection 
(%)
p Total (%) coinfection 
(%)
p
Total 1047 (100) 42 (4) 1136 (100) 203 (17.9) 1076 (100) 31 (2.9)
Jail
Cassino 502 (47.9) 11 (2.2) 510 (44.9) 56 (11.0) 505(46.9) 10(2.0)
Frosinone 485 (46.3) 30 (6.2) 0.004 494 (43.5) 96 (19.4) < 0.001 511(47.5) 19(3.7) 0.248
Latina 60 (5.8) 1 (1.7) 132 (11.6) 51 (38.6) 60 (5.6) 2 (3.3)
Tot 1047 42 1136 203 1076 31
Nationality
Italian 773 (73.8) 39 (5) 834 (73.4) 32 (3.8) 787(73.1) 28(3.6)
Foreign 274 (26.2) 3 (1.1) 0.007 302 (26.6) 171 (56.6) < 0.001 289(26.9) 3 (1.0) 0.029
Tot 1047 42 1136 203 1076 31
Civil status
Single 423 (51.5) 16 (3.8) 441(51.8) 14(3.2)
Married 240 (29.2) 5 (2.1) 468 (51.8) 105 (22.4) 247(29.0) 4(1.6)
Cohabitant 73 (9.0) 10 (13.7) < 0.001 275 (30.4) 36 (13.1) 0.013 74 (8.7) 7(9.5) 0.020
Separated 71 (8.6) 4 (5.6) 75 (8.3) 15 (20.0) 74(8.7) 2(2.7)
Widower 14 (1.7) 2 (14.3) 73 (8.1) 19 (26.0) 15(1.8) 1(6.7)
Tot 821 37 13 (1.4) 4 (30.8) 851 28
904 179
Age group
18–24 211 (20.8) 1 (0.5) 234 (23.1) 32 (12.1) 215(20.4) 0 (0)
25–34 469 (46.4) 21 (4.5) 507 (50.0) 114 (22.5) 482(45.8) 16(3.3)
35–44 238 (23.5) 17 (7.1) 0.003 255 (25.2) 47 (18.4) < 0.001 245 (23.3) 13 (5.3) 0.003
≥ 45 94 (9.3) 1 (1.1) 101 (10.0) 5 (4.9) 98(9.3) 0 (0)
Tot 1013 40 1097 198 1040 29
Educational 
level
Illiterate 33 (3.7) 0 (0)
Elementary 
school
300 (38.2) 13 (4.3) 33 (3.9) 1 (3.0) 36 (4.6) 0(0)
Jumior high 
school
346 (46.3) 16 (4.6) 0.535 339 (40.5) 63 (18.6) 0.018 309(39.8) 9(2.9) 0.784
Senior high 
school
64 (10.6) 1 (18.9) 382 (45.7) 92 (24.1) 358(46.1) 8(2.2)
Degree 8 (1.2) 0 (0) 73 (8.7) 11 (15.1) 65(8.4) 1(1.5)
Tot 751 39 9 (1.1) 1(11.1) 9(1.2) 0(0)
836 168 777 18
Num. of 
detentions
First 
detention
682 (68.8) 21 (3.1) 734 (68.2) 129 (17.6) 689(67.7) 16(2.3)
> 1 detention 309 (31.2) 20 (6.5) 0.016 342 (31.8) 65 (19.0) 0.570 328(32.3) 13(4.0) 0.142
Tot 991 41 1076 194 1017 29BMC Infectious Diseases 2007, 7:100 http://www.biomedcentral.com/1471-2334/7/100
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cational level, 667 prisoners had an elementary or junior
high school degree and 17 of them had a HBV/HCV coin-
fection, furthermore, only 9, of the inmates had a tertiary
level degree and none of them had coinfections.
Statistically significant differences were found for nation-
ality (p = 0.029), civil status (p = 0.020), age group (p =
0.003), drug addiction (p < 0.001) and smoking status (p
= 0.004). (Tables 1 and 2)
The association between the use of methadone and HIV/
HCV coinfection was almost significant (p = 0.057).
The regression analysis showed that factors associated
with HIV/HBV coinfection seropositivity, were drug
Table 2: Health status characteristics, according to seropositivity against HIV/HCV, HBV/HCV and HIV/HBV coinfection among 
inmates in Southern Lazio
HIV/HCV HBV/HCV HIV/HBV
Characteri
stic
Total (%) coinfection 
(%)
P Total (%) coinfection 
(%)
p Total (%) coinfection 
(%)
p
Drug 
addiction
No 516 (49.3) 2 (0.4) 574 (50.5) 44 (7.7) 531 (49.3) 2 (0.47)
Yes 479 (45.7) 36 (7.5) 512 (45.1) 148 (28.9) 494 (45.9) 28 (5.7)
Former 52 (5) 4 (7.7) < 0.001 50 (4.4) 11 (22.0) < 0.001 51 (4.7) 1 (2.0) < 0.001
Tot 1047 42 1086 203 1076 31
Drug type
Heroin 429 (41) 40 (9.3) 450 (39.6) 148 (32.9) 438 (40.7) 29 (6.6)
Cocaine 264 (25.2) 18 (6.8) 280 (24.6) 83 (29.6) 272 (25.3) 14 (5.1)
Tot 693 58 730 231 1076 43
Use of 
methadone
No 38 (14.4) 0 (0) 261(73.1) 35 (13.4) 249 (87.1) 22 (8.8)
Yes 245 (85.6) 32 (13.1) 0.012 96 (26.9) 95 (99.0) 0.992 38 (13.3) 0 (0) 0.057
Tot 283 32 357 130 286 22
VDRL
Positive 14 (1.5) 2 (14.3) 14 (1.4) 3 (21.4) 19 (1.9) 1 (5.3)
Negative 972 (98.5) 34 (3.5) 0.09 982 (98.6) 173 (17.6) 993 (98.1) 26 (2.6) 0.479
Tot 986 36 996 176 0.71 1012 27
Previous 
sexually 
transmitted
diseases 30 (3.2) 3 (10) 32 (3.1) 8 (25) 35 (3.7) 2 (5.7)
Yes 900 (96.8) 31 (3.4) 0.092 983 (98.8) 182 (18.5) 0.355 922 (96.3) 24 (2.6) 0.226
No 930 34 1015 190 957 26
Tot
Tine test
Positive 38 (4.5) 0 (0) 41 (4.5) 8 (19.5) 39 (4.3) 2 (5.1)
Negative 856 (95.5) 34 (4.0) 868 (95.5) 154 (17.7) 873 (95.7) 24 (2.7) 0.382
Tot 894 34 0.393 909 162 0.772 912 26
Alcohol abuse
Yes 95 (9.3) 6 (6.3) 103 (9.3) 21 (20.4) 99 (9.4) 5 (5.0)
No 925 (90.7) 36 (3.9) 0.272 1006 (90.7) 178 (17.7) 0.497 950 (90.6) 25 (2.6) 0.169
Tot 1020 42 1109 199 1049 30
Smoking 
status
Yes 717 (69.6) 38 (5.3) 778 (69.5) 160 (20.6) 739(69.8) 28 (3.8)
No 313 (30.4) 4 (1.3) 0.002 342 (30.5) 39 (11.4) < 0.001 320(30.2) 2 (0.6) 0.004
Tot 1030 42 1120 199 1059 30BMC Infectious Diseases 2007, 7:100 http://www.biomedcentral.com/1471-2334/7/100
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addiction (OR = 23.57, p= 0.002), age group (OR = 2.99,
p = 0.006, for people of 35–44 years, Italian nationality
(OR = 4.25, p = 0.04) and civil status (OR = 2.84, p =
0.028, for cohabitants) (Table 3).
Discussion
This cross-sectional study carried out in the jails in South-
ern Lazio showed a prevalence of HIV/HCV, HBV/HCV
and HIV/HBV coinfections of about 4%, 18% and 3% in
inmates, respectively. Data regarding these coinfections
prevalence, even if remarkable, could however represent a
biased estimation of the phenomenon, as screening for
these infections are not mandatory for all prisoners. In our
study the percentage of prisoners actually subjected to
HIV testing was 47.37% of all prisoners. This particular
situation could be due to the fact that all of the peniten-
tiaries examined in our study are jails where the prisoners
are confined waiting for judgement or condemned to
punishments less than 5 years.
As depicted in other international studies, our study
showed that HIV, HBV and HCV sero-positivities coinfec-
tions are strictly associated with the status of drug addic-
tion, especially intravenous heroin addiction. Moreover,
the spread of HIV and viral liver infections is due to needle
sharing, the most important risk related factor, confirm-
ing the results of similar national [49-51] and interna-
tional investigations [7,8,12,17,28,29,31,39,41,42,52-
54].
Furthermore, HIV, HBV and HCV sero-positivities are
influence by civil status, being a widower or cohabitant is
significantly associated with these coinfections.
Finally, it is possible to consider that even if health man-
agement of HBV, HCV and HIV sero-positivities in jails
appears worrisome, there is paradoxically an opportunity
for these patients of receiving good treatment inside the
prison environment [55].
Table 3: Factors associated with HIV/HCV, HBV/HCV and HIV/HBV coinfections among inmates in Southern Lazio
HIV/HCV HBV/HCV HIV/HBV
Characteristic OR (95%CI) p OR (95%CI) p OR (95%CI) p
Drug addiction
No (reference 
group)
111
Yes 16.02 (3.79 – 
67.74)
0.012 4.15 (2.83 – 6.09) < 0.001 23.57 (3.16 – 
175.83)
0.002
Age group (years)
< 35 (reference 
group)
111
35 – 44 2.83 (1.42 – 5.61) 0.004 1.01 (0.68 – 1.49) 0.970 2.99 (1.39 – 6.53) 0.006
≥ 45 0.91 (0.11 – 7.76) 0.933 0.371 (1.14 – 0.95) 0.040 n.a. n.a.
Smoking status
No (reference 
group)
111
Yes 3.73 (1.11 – 12.56) 0.033 1.417 (0.950 – 
2.11)
0.088 4.25 (0.98 – 18.40) 0.053
Nationality
Foreign (reference 
group)
111
Italian 7.05 (1.64 – 30.31) 0.009 2.310 (1.506 – 
3.54)
< 0.001 4.61 (1.07 – 19.92) 0.040
Civil Status
Single (reference 
group)
111
Cohabitant 3.09 (1.37 – 6.97) 0.007 0.68 (0.36 – 1.27) 0.227 2.84 (1.12 – 7.19) 0.028
Married 0.70 (0.23 – 2.13) 0.534 0.86 (0.56 – 1.33) 0.500 0.71 (0.20– 2.54) 0.598
Divorced 0.76 (0.23 – 2.48) 0.649 0.78 (0.25 – 2.52) 0.701 0.82 (0.21 – 2.51) 0.636
Goodness of fit χ2 = 0.719 χ2 = 1.649 χ2 = 2.234
H-L test p = 0.998 p = 0.895 p = 0.946
n.a. = not applicableBMC Infectious Diseases 2007, 7:100 http://www.biomedcentral.com/1471-2334/7/100
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Our study has some limitations. One weakness is infor-
mation bias. The study was based on the information
gathered from the clinical charts, which may not have
been complete in defining inmates' health status and
diagnostics. Moreover, for some variables, such as educa-
tional level, and civil status, gathered data were not com-
plete.
It is not known whether the study population is represent-
ative of the whole populations of participating prisons. It
is possible that drug addicts were more likely to be given
a HIV, HBV and HCV test, in which case an overestima-
tion of the prevalence rates of infections could occur. In
this case, if we hypothesize that all prisoners not given a
test were seronegative, we would find a prevalence of
2.45%, 10.9% and 11.6%, respectively.
A fundamental role in the control of infection from HIV
in prison environments may be found through preven-
tion. As prisoner populations are at high risk for all of
these infections, it is necessary for public health and insti-
tutions to collaborate to develop HBV, HCV, HIV preven-
tion programs, including immunization, health
education and substance abuse treatment. It is worrisome
that not all prisoners are submitted to screening of these
infections, while in other countries mandatory drug and
blood tests exists [56].
In waiting for a positive evolution in the preparation of a
sure and immunological vaccine, the application of direct
and indirect prophylaxis measures represents the more
convenient way to combat the AIDS problem in prisons.
The second fundamental aspect of the preventive strategy
against HIV/AIDS in the prison environment is the thor-
ough observance of hygiene rules either general or specific
(i.e., personal use of razors, teeth brush), which are often
neglected, even the most elementary ones.
The overcrowding of prisons and the consequent discom-
fort either among the warders or among the prisoners has
become one of the most urgent problems to face. As
reported by the WHO guideline to the essentials in prison
health, the living conditions in most prisons of the world
are unhealthy and rates of infection with HIV and hepati-
tis are much higher than in the general population [57].
Concerns exist that prisons could serve as a reservoir for
the amplification of the transmission of infectious dis-
eases in the wider community after the release of inmates
who have became infected while incarcerated [2].
Of those identified as being infected in prison, 85% of
cases were associated with pre-incarceration behaviours
[35,36]. The restrictive nature of the prison environment
and the scarcity of clean syringes and condoms probably
heighten the hazards associated with high risk activities,
thus increasing the risk of transmission from infected to
uninfected inmates [37].
The scientific literature shows a strong connection
between infection from HIV, HBV, HCV and the group of
drug-addicts in which some risk factors are surely present
[38,39]. As shown in many studies, it is clear that
although the jail can reduce the consumers of drugs by
parenteral mean, the risk to contract the infections from
HIV, HBV, and HCV would increase for people who con-
tinue to inject toxic substances [40,41].
In conclusion, our study points out that within the
inmates population a resevoir of infected individuals
exists, and that the jails could represent a pivotal target for
primary prevention programs (for inmates, for prison
guard and for the general population when an inmate
leaves the jail), secondary prevention (in order to reduce
the clinical risks for progression of liver disease and AIDS,
and to reduce costs for management complicated infec-
tion) and tertiary prevention (to guarantee prisoners right
of health).
Conclusion
To control the diffusion of infectious diseases, and above
all HIV, in prisons, implementation of operative guide-
lines and adequate funding are needed. It is therefore nec-
essary to promote epidemiological studies and cost
analyse of the economic impact relating to the public
health of prisoners with coinfection management, in
order to know the real burden of the problem.
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